Metagenomi (NASDAQ:MGX) Announces Quarterly Earnings Results

Metagenomi (NASDAQ:MGX) issued its quarterly earnings data on Thursday. The company reported ($0.60) earnings per share (EPS) for the quarter, FiscalAI reports. Metagenomi had a negative return on equity of 43.19% and a negative net margin of 287.06%.The firm had revenue of $3.91 million for the quarter.

Metagenomi Stock Up 0.6%

Shares of Metagenomi stock traded up $0.01 during trading on Thursday, reaching $1.61. The company’s stock had a trading volume of 275,386 shares, compared to its average volume of 250,054. The company has a market capitalization of $60.46 million, a P/E ratio of -0.67 and a beta of 0.45. Metagenomi has a 12-month low of $1.23 and a 12-month high of $3.95. The business has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.93.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Institutional Investors Weigh In On Metagenomi

A number of institutional investors and hedge funds have recently modified their holdings of the company. Pura Vida Investments LLC increased its holdings in Metagenomi by 260.1% during the 2nd quarter. Pura Vida Investments LLC now owns 952,134 shares of the company’s stock valued at $1,409,000 after acquiring an additional 687,743 shares in the last quarter. Good Life Advisors LLC increased its position in Metagenomi by 100.0% during the second quarter. Good Life Advisors LLC now owns 200,000 shares of the company’s stock worth $296,000 after purchasing an additional 100,000 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Metagenomi during the first quarter valued at about $119,000. XTX Topco Ltd increased its stake in Metagenomi by 353.4% during the fourth quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock worth $112,000 after acquiring an additional 53,778 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Metagenomi by 482.9% during the fourth quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock worth $76,000 after acquiring an additional 17,491 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.